CD56在多发性骨髓瘤诊断及分型中的临床应用

Clinical application of CD56 in the diagnosis and classification of multiple myeloma

目的探讨CD56在多发性骨髓瘤诊断及分型中的临床应用意义。方法研究于2017年1月至2018年7月开展,收集赣南医学院第一附属医院初次进行诊治的多发性骨髓瘤患者52例,正常人17例。采用美国BDFACSCalibur型流式细胞仪采集数据,检测浆细胞的免疫表型。取69例对象骨髓标本,标记CD45、CD38、CD138、CD56、CD19、CD117、CD34、CD20、CD22、CD33、CD9、DR、cKappa、cLambda及骨髓比例进行检测,分析其免疫表型特点。结果多发性骨髓瘤患者中CD56表达率76.9%;多发性骨髓瘤患者中M蛋白表达率为76.9%。结论CD56在多发性骨髓瘤诊断中,是区分良、恶性浆细胞的重要标志;CD56表达患者中以IgG型最为常见。

Objective To investigate the clinical significance of CD56 in the diagnosis and classification of multiple myeloma. Methods From January 2017 to July 2018, the study was conducted to collect 52 patients with multiple myeloma who were initially diagnosed and treated in the First Affiliated Hospital of Wannan Medical College, and 17 normal subjects. Data were collected using a US BD FACS Calibur flow cytometer to detect the immunophenotype of plasma cells. 69 specimens of bone marrow were collected and the ratios of CD45, CD38, CD138, CD56, CD19, CD117, CD34, CD20, CD22, CD33, CD9, DR, cKappa, cLambda and bone marrow were detected to analyze the immunophenotypic characteristics. Results The expression rate of CD56 in patients with multiple myeloma was 76.9%. The expression rate of M protein in patients with multiple myeloma was 76.9%. Conclusion CD56 is an important marker for distinguishing between benign and malignant plasma cells in the diagnosis of multiple myeloma. IgG is the most common in patients with CD56 expression.